HRP20100473T1 - Imunostimulatorne kombinacije za profilaksu i liječenje hepatitisa c - Google Patents
Imunostimulatorne kombinacije za profilaksu i liječenje hepatitisa c Download PDFInfo
- Publication number
- HRP20100473T1 HRP20100473T1 HR20100473T HRP20100473T HRP20100473T1 HR P20100473 T1 HRP20100473 T1 HR P20100473T1 HR 20100473 T HR20100473 T HR 20100473T HR P20100473 T HRP20100473 T HR P20100473T HR P20100473 T1 HRP20100473 T1 HR P20100473T1
- Authority
- HR
- Croatia
- Prior art keywords
- combination according
- immunostimulatory combination
- immunostimulatory
- hepatitis
- treatment
- Prior art date
Links
- 230000003308 immunostimulating effect Effects 0.000 title claims abstract 21
- 238000011282 treatment Methods 0.000 title claims abstract 6
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 5
- 229940123189 CD40 agonist Drugs 0.000 claims abstract 4
- 208000005176 Hepatitis C Diseases 0.000 claims abstract 4
- 238000011321 prophylaxis Methods 0.000 claims abstract 4
- 239000012634 fragment Substances 0.000 claims abstract 3
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 claims abstract 3
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 2
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims abstract 2
- 239000000556 agonist Substances 0.000 claims abstract 2
- 230000004044 response Effects 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 4
- 241000711549 Hepacivirus C Species 0.000 claims 3
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 108700012707 hepatitis C virus NS3 Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Imunostimulatorna kombinacija za profilaksu i liječenje hepatitisa C, naznačena time što sadrži: a) Poli(I:C) koji djeluje kao agonist TLR3, b) agonist CD40 ili sekvenca DNK koja ga kodira, i c) polipeptid, koji sadrži NS3 protein virusa hepatitisa C, ili fragment navedenog NS3 proteina sa kapacitetom za indukciju CD8+ i CD4+ odgovora. Patent sadrži još 17 patentnih zahtjeva.
Claims (18)
1. Imunostimulatorna kombinacija za profilaksu i liječenje hepatitisa C, naznačena time što sadrži:
a) Poli(I:C) koji djeluje kao agonist TLR3,
b) agonist CD40 ili sekvenca DNK koja ga kodira, i
c) polipeptid, koji sadrži NS3 protein virusa hepatitisa C, ili fragment navedenog NS3 proteina sa kapacitetom za indukciju CD8+ i CD4+ odgovora.
2. Imunostimulatorna kombinacija prema patentnom zahtjevu 1, naznačena time što je agonist CD40 izabran od anti-CD40 antitijela, CD40L, i fragmenata prethodno navedenog koji imaju očuvan kapacitet za vezivanje sa CD40.
3. Imunostimulatorna kombinacija prema patentnom zahtjevu 2, naznačena time što je agonist CD40 - anti-CD40 antitijelo.
4. Imunostimulatorna kombinacija prema patentnom zahtjevu 1, naznačena time što sadrži:
a) poli(I:C),
b) anti-CD40 antitijelo, i
c) polipeptid koji sadrži NS3 protein.
5. Imunostimulatorna kombinacija prema patentnom zahtjevu 3 ili 4, naznačena time što je polipeptid koji sadrži NS3 protein, polipeptid sa SEQ ID. NO: 1.
6. Imunostimulatorna kombinacija prema bilo kojem od patentnih zahtjeva 1 do 5 naznačena time što sve komponente formiraju dio jedne farmaceutske kompozicije.
7. Imunostimulatorna kombinacija prema bilo kojem od patentnih zahtjeva 1 do 5 naznačena time što sve komponente formiraju dio najmanje dvije različite farmaceutske kompozicije.
8. Primjena imunostimulatorne kombinacije prema bilo kojem od patentnih zahtjeva 1 do 7, naznačena time što se koristi u pripremi lijeka za profilaksu i liječenje hepatitisa C.
9. Primjena imunostimulatorne kombinacije prema bilo kojem od patentnih zahtjeva 1 do 7, naznačena time što se koristi u pripremi lijeka za liječenje hepatitisa C.
10. Primjena imunostimulatorne kombinacije prema patentnim zahtjevima 8 ili 9, naznačena time što navedeni lijek sadrži najmanje dvije farmaceutske kompozicije pogodne za istovremenu primjenu.
11. Primjena imunostimulatorne kombinacije prema patentnim zahtjevima 8 ili 9, naznačena time što navedeni lijek sadrži najmanje dvije farmaceutske kompozicije pogodne za odvojenu primjenu.
12. Primjena imunostimulatorne kombinacije prema patentnom zahtjevu 11, naznačena time što su navedene farmaceutske kompozicije pogodne za odvojenu primjenu različitim načinima primjene.
13. Farmaceutska kompozicija koja sadrži imunostimulatornu kombinaciju prema bilo kojem od patentnih zahtjeva 1 do 5, naznačena time što je svaka od komponenti prisutna u farmaceutski prihvatljivim količinama.
14. Komplet za primjenu imunostimulatorne kombinacije prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time što sadrži najmanje dvije različite farmaceutske kompozicije kao što su definirane u patentnom zahtjevu 13, pri čemu svaka od njih sadrži najmanje jednu od komponenti a), b) ili c) navedene imunostimulatorne kombinacije kao što je definirano u patentnom zahtjevu 1.
15. Imunostimulatorna kombinacija prema bilo kojem od patentnih zahtjeva 1 do 7, naznačena time, što se koristi u efikasnoj količini za indukciju imunog odgovora na virus hepatitisa C.
16. Imunostimulatorna kombinacija prema patentnom zahtjevu 15, naznačena time, što se koristi za primjenu kao profilaktički tretman.
17. Imunostimulatorna kombinacija prema patentnom zahtjevu 15, naznačena time, što se koristi za primjenu kao terapeutski tretman.
18. Cjepivo protiv virusa hepatitisa C, naznačeno time što sadrži imunostimulatornu kombinaciju prema bilo kojem od patentnih zahtjeva 1 do 7.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200502446 | 2005-10-07 | ||
| ES200601563A ES2334472B1 (es) | 2006-06-09 | 2006-06-09 | Combinacion inmunoestimuladora para profilaxis y tratamiento de hepatitis c. |
| PCT/ES2006/000554 WO2007042583A1 (es) | 2005-10-07 | 2006-10-05 | Combinación inmunoe s t imuladora para profilaxis y tratamiento de hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100473T1 true HRP20100473T1 (hr) | 2010-10-31 |
Family
ID=37942331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100473T HRP20100473T1 (hr) | 2005-10-07 | 2010-08-30 | Imunostimulatorne kombinacije za profilaksu i liječenje hepatitisa c |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20100047231A1 (hr) |
| EP (1) | EP1949913B1 (hr) |
| JP (1) | JP2009511452A (hr) |
| CN (1) | CN101330928B (hr) |
| AT (1) | ATE469657T1 (hr) |
| AU (1) | AU2006301171B9 (hr) |
| BR (1) | BRPI0616978A2 (hr) |
| CA (1) | CA2625506C (hr) |
| CY (1) | CY1110744T1 (hr) |
| DE (1) | DE602006014720D1 (hr) |
| DK (1) | DK1949913T3 (hr) |
| ES (1) | ES2346570T3 (hr) |
| HR (1) | HRP20100473T1 (hr) |
| PL (1) | PL1949913T3 (hr) |
| PT (1) | PT1949913E (hr) |
| RS (1) | RS51402B (hr) |
| RU (1) | RU2431499C2 (hr) |
| SI (1) | SI1949913T1 (hr) |
| WO (1) | WO2007042583A1 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101460551B1 (ko) * | 2006-09-18 | 2014-11-18 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 면역 반응을 향상시키는 조성물 및 방법 |
| US9125854B2 (en) | 2007-10-30 | 2015-09-08 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
| JP5480812B2 (ja) | 2007-11-01 | 2014-04-23 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | アイメリアに対する免疫応答を強化する組成物および方法 |
| AU2009323996A1 (en) | 2008-12-03 | 2011-07-07 | Institut Pasteur | Use of phenol-soluble modulins for vaccine development |
| CN102741295A (zh) | 2009-03-10 | 2012-10-17 | 贝勒研究院 | 靶向抗原呈递细胞的抗病毒疫苗 |
| PL2525817T3 (pl) | 2010-01-21 | 2018-01-31 | Univ Arkansas | Wektory szczepionkowe i sposoby wzmacniania odpowiedzi immunologicznych |
| NZ702839A (en) | 2010-06-09 | 2016-04-29 | Univ Arkansas | Vaccine and methods to reduce campylobacter infection |
| MY173328A (en) | 2013-02-14 | 2020-01-16 | Texas A & M Univ Sys | Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection |
| BR112015023024B1 (pt) | 2013-03-15 | 2022-04-19 | The Board Of Trustees Of The University Of Arkansas | Vetor de vacina e composições farmacêuticas compreendendo o mesmo |
| BR112018072592A2 (pt) | 2016-05-03 | 2019-04-16 | The Board Of Trustees Of The University Of Arkansas | vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049390A (en) * | 1987-09-02 | 1991-09-17 | Allergy Immuno Technologies, Inc. | Liposome containing immunotherapy agents for treating IgE mediated allergies |
| US6951646B1 (en) * | 1998-07-21 | 2005-10-04 | Genmab A/S | Anti hepatitis C virus antibody and uses thereof |
| US7022830B2 (en) * | 2000-08-17 | 2006-04-04 | Tripep Ab | Hepatitis C virus codon optimized non-structural NS3/4A fusion gene |
| WO2002014362A2 (en) * | 2000-08-17 | 2002-02-21 | Tripep Ab | A hepatitis c virus non-structural ns3/4a fusion gene |
| EP2258712A3 (en) * | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
| EP2572714A1 (en) * | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
-
2006
- 2006-10-05 PT PT06830863T patent/PT1949913E/pt unknown
- 2006-10-05 AU AU2006301171A patent/AU2006301171B9/en not_active Ceased
- 2006-10-05 EP EP06830863A patent/EP1949913B1/en active Active
- 2006-10-05 CA CA2625506A patent/CA2625506C/en not_active Expired - Fee Related
- 2006-10-05 WO PCT/ES2006/000554 patent/WO2007042583A1/es active Application Filing
- 2006-10-05 US US12/083,217 patent/US20100047231A1/en not_active Abandoned
- 2006-10-05 DE DE602006014720T patent/DE602006014720D1/de active Active
- 2006-10-05 SI SI200630732T patent/SI1949913T1/sl unknown
- 2006-10-05 DK DK06830863.4T patent/DK1949913T3/da active
- 2006-10-05 CN CN2006800457078A patent/CN101330928B/zh not_active Expired - Fee Related
- 2006-10-05 RS RSP-2010/0373A patent/RS51402B/en unknown
- 2006-10-05 RU RU2008117328/15A patent/RU2431499C2/ru not_active IP Right Cessation
- 2006-10-05 ES ES06830863T patent/ES2346570T3/es active Active
- 2006-10-05 BR BRPI0616978-3A patent/BRPI0616978A2/pt not_active IP Right Cessation
- 2006-10-05 JP JP2008534032A patent/JP2009511452A/ja active Pending
- 2006-10-05 AT AT06830863T patent/ATE469657T1/de active
- 2006-10-05 PL PL06830863T patent/PL1949913T3/pl unknown
-
2010
- 2010-08-19 CY CY20101100769T patent/CY1110744T1/el unknown
- 2010-08-30 HR HR20100473T patent/HRP20100473T1/hr unknown
-
2013
- 2013-09-27 US US14/039,269 patent/US20140056943A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SI1949913T1 (sl) | 2011-02-28 |
| DK1949913T3 (da) | 2010-10-04 |
| EP1949913B1 (en) | 2010-06-02 |
| PT1949913E (pt) | 2010-08-24 |
| RS51402B (en) | 2011-02-28 |
| US20140056943A1 (en) | 2014-02-27 |
| CN101330928B (zh) | 2012-11-14 |
| CA2625506A1 (en) | 2007-04-19 |
| ES2346570T3 (es) | 2010-10-18 |
| DE602006014720D1 (de) | 2010-07-15 |
| RU2008117328A (ru) | 2009-11-20 |
| PL1949913T3 (pl) | 2010-10-29 |
| BRPI0616978A2 (pt) | 2011-07-05 |
| AU2006301171B9 (en) | 2012-03-29 |
| CY1110744T1 (el) | 2015-06-10 |
| WO2007042583A1 (es) | 2007-04-19 |
| CN101330928A (zh) | 2008-12-24 |
| AU2006301171B2 (en) | 2011-10-27 |
| ATE469657T1 (de) | 2010-06-15 |
| RU2431499C2 (ru) | 2011-10-20 |
| EP1949913A1 (en) | 2008-07-30 |
| US20100047231A1 (en) | 2010-02-25 |
| CA2625506C (en) | 2014-06-10 |
| AU2006301171A1 (en) | 2007-04-19 |
| JP2009511452A (ja) | 2009-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100473T1 (hr) | Imunostimulatorne kombinacije za profilaksu i liječenje hepatitisa c | |
| Quan et al. | Ginseng and Salviae herbs play a role as immune activators and modulate immune responses during influenza virus infection | |
| EA200601761A1 (ru) | Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения | |
| EP3419643A1 (en) | Smc combination therapy for the treatment of cancer | |
| NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
| BRPI0707779B8 (pt) | antígeno isolado, composição de vacina e método para produção de uma proteína antígeno | |
| BRPI0606867A2 (pt) | formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico | |
| MX2009001412A (es) | Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas. | |
| EA200702656A1 (ru) | Составы, содержащие пептиды, стимулирующие рецептор эритропоэтина, и их применение | |
| JP2009511452A5 (hr) | ||
| EA200801411A1 (ru) | Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях | |
| MY197684A (en) | Oncolytic virus and method | |
| JP5745577B2 (ja) | Ｃｄ４０アゴニスト抗体／ｉ型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用 | |
| Ellerhoff et al. | Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus | |
| MX2023000041A (es) | Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus. | |
| AR053899A1 (es) | Formulaciones que continen glimepirida y/o sus sales | |
| AR054259A1 (es) | Vacuna contra virus de papiloma humano (hpv) | |
| HRP20150363T1 (hr) | Kompozicije koje sadrže core-1 pozitivni mikroorganizam i njihova primjena za lijeäśenje ili profilaksu tumora | |
| WO2006072946A3 (en) | Hsp60, hsp60 peptides and t cell vaccines for immunomodulation | |
| NO20051561L (no) | Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine. | |
| MX2011004176A (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo. | |
| DK1537204T3 (da) | Granzym B som HSP70/HSP70-peptidafhængig udløser af programmeret celledød hos tumorceller | |
| SG148195A1 (en) | Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof | |
| AU2003240790A1 (en) | Antibody peg positional isomers, compositions comprising same, and use thereof | |
| MX2021013018A (es) | Formulacion de arnm. |